Pharmaceuticals company Caplin Point Laboratories announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: Revenue from Operation: Rs 435.50 crore, increased by 17.0% compared to Q3FY23. Total Revenue: Rs 452.68 crore, increased by 17.2% compared to Q3FY23. Gross Profit: Rs 245.39 crore, increased by 17.9% compared to Q3FY23. Gross Margin%: 56.3%, increased from 55.9% in Q3FY23. EBITDA: Rs 159.46 crore, increased by 29.1% compared to Q3FY23. EBITDA Margin%: 35.2%, increased from 32.0% in Q3FY23. PBT: Rs 145.41 crore, increased by 30.1% compared to Q3FY23. PBT Margin%: 32.1%, increased from 28.9% in Q3FY23. PAT: Rs 119.82 crore, increased by 23.0% compared to Q3FY23. PAT Margin%: 26.5%, increased from 25.2% in Q3FY23. Consolidated 9MFY24: Revenue from Operation: Rs 1,240.88 crore, increased by 15.2% compared to 9MFY23. Total Revenue: Rs 1,290.53 crore, increased by 15.0% compared to 9MFY23. Gross Profit: Rs 708.07 crore, increased by 19.8% compared to 9MFY23. Gross Margin%: 57.1%, increased from 54.8% in 9MFY23. EBITDA: Rs 455.86 crore, increased by 26.0% compared to 9MFY23. EBITDA Margin%: 35.3%, increased from 32.2% in 9MFY23. PBT: Rs 418.40 crore, increased by 27.8% compared to 9MFY23. PBT Margin%: 32.4%, increased from 29.2% in 9MFY23. PAT: Rs 340.19 crore, increased by 23.4% compared to 9MFY23. PAT Margin%: 26.4%, increased from 24.6% in 9MFY23. Commenting on the performance, C.C. Paarthipan, Chairman said: "Consistency has always been a key area for our company and this Quarter is no different. The company delivered strong results, reporting Revenue from Operations of Rs 436 crore, resulting in a 17% YoY growth. Net Profit amounted to Rs 120 crore, reflecting a 23% YoY growth, with margins at 27%. Approval from Colombia’s INVIMA for our Caplin Steriles site will accelerate growth in newer markets like Mexico, Chile and Colombia, reinforcing our commitment to high regulatory standards and positioning us for success. We remain committed to driving sustainable growth with strong cashflows". Result PDF
